Clinical trials: Eye Pain
Post-operative Pain Control
Post-operative Pain Control After Photorefractive Keratectomy Comparing Acetaminophen/Codeine vs Acetaminophen/Oxycodone
Photorefractive keratectomy (PRK) is a refractive error correction procedure that helps eliminate or reduce the dependence on corrective lenses. An important aspect of PRK is post-operative pain management.
- Trial name
- NCT04399122
- Testing
- acetaminophen/codeine vs acetaminophen/oxycodone
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- 59th Medical Wing
Cataract
Nepafenac Compared to Placebo for Ocular Pain and Inflammation
The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery…
- Trial name
- NCT01426854
- Testing
- Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle Ophthalmic Solution
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Alcon Research
Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension Treatment Trial
Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a disorder of elevated intracranial pressure of unknown cause [Corbett, et al., 1982; Wall, et al., 1991].
- Trial name
- IIHTT (NCT01003639)
- Testing
- Acetazolamide, Formal weight loss counselling program
- Where
- 41 sites in United States, Canada
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Keratoconus, Unstable, Collagen Crosslinking
Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
There is no standard of care medication regimen for the management of pain and inflammation post-corneal crosslinking (CXL), although most cornea specialists agree on use of an antibiotic and steroid eye drop in the immediate…
- Conditions
- Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
- Trial name
- NCT04168112
- Testing
- Dextenza, Prednisolone Acetate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sight Medical Doctors PLLC
Pain, Inflammation
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
This is an efficacy study of Bromfenac Ophthalmic Solution in cataract surgery.
- Conditions
- Pain, Inflammation, Cataract
- Trial name
- NCT01367249
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Bausch & Lomb Incorporated
Refractive Surgery
The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study
To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to standard steroid drop regimen in the contralateral eye following bilateral PRK surgery.
- Trial name
- NCT04396990
- Testing
- Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vance Thompson Vision
Chronic Ocular Pain
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and…
- Trial name
- NCT04630158
- Testing
- SAF312
- Where
- 28 sites in United States, Japan and 1 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Inflammation, Pain
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01298752
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Headache Migraine Chronic
Spectacle Tints and Thin-Films for Migraine
Nearly all migraine sufferers report sensitivity to light during a headache and a significant proportion of sufferers report light sensitivity between attacks. Light is also a common trigger for migraine headaches.
- Trial name
- NCT02720211
- Testing
- Gray tinted spectacle lenses, Thin-Film spectacle lenses
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-1 (NCT04246801)
- Testing
- Clobetasol propionate, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- Salvat
Retinal Detachment
Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery
PURPOSE: Scleral buckle surgery is a widely used ophthalmic surgery for the correction of rhegmatogenous retinal detachment. Studies suggest that eye pain is a common and underestimated occurrence after scleral buckle surgery…
- Trial name
- NCT04701593
- Testing
- Triamcinolone Acetonide 40mg/mL
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Polytechnic Institute and State University
Inflammation, Pain
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate ophthalmic gel
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01996839
- Testing
- Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle (BID)
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation, Pain
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02208297
- Testing
- Loteprednol Etabonate Gel (BID), Vehicle Gel (BID)
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Bausch & Lomb Incorporated
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cataract
Nepafenac 0.3% Two Study
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01318499
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Vehicle 0.3%
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Alcon Research
Cornea
Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain
This study is a prospective, interventional, open-label, single arm, non-randomized trial treating 30 patients with peripheral or mixed neuropathic corneal pain at their baseline exam and following 45 days and 90 days of daily…
- Trial name
- INSTANT (NCT03674892)
- Testing
- TrueTear™ intranasal neurostimulator (ITN)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Tufts Medical Center
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.